Research Highlights
Pioneering Precision Therapeutics for CMT1A
CELLTIUM is dedicated to developing precision therapeutics for Charcot–Marie–Tooth disease (CMT), the most common inherited peripheral neuropathy.
CMT1A, caused by a duplication of the PMP22 gene (17p12), leads to progressive demyelination and axonal loss. Despite significant medical need, there are currently no approved disease-modifying therapies (DMTs) capable of altering the disease course.
Leveraging proprietary precision neurotechnology, CELLTIUM is developing CMT1A-tailored interventions that directly target myelin pathology. Our goal is to move beyond symptomatic relief to fundamentally modify disease progression.
Challenges & Opportunities
Overcoming the Barriers of CMT1A Drug Discovery
While the genetic driver of CMT1A (PMP22 duplication) is known, the precise pathogenic mechanisms remain complex, limiting the success of conventional target-based discovery.
Current therapeutic strategies primarily focus on neuronal or axonal preservation. While these approaches offer neuroprotective benefits, they may not fully address the root cause: Schwann cell dysfunction and myelin damage. Furthermore, reliance on repurposed drugs often leaves significant unmet medical needs for CMT1A patients.
CELLTIUM overcomes these limitations with a precision therapeutic strategy that directly targets peripheral myelinopathy, addressing the disease at its core.
Platform Technology
The PRECISION™ High-Content Screening (HCS) Platform
CELLTIUM’s PRECISION™ HCS platform integrates proprietary disease models with machine learning and automation. It faithfully recapitulates CMT1A peripheral nerve pathology, bridging the gap between bench and bedside.
-
Proprietary Co-Culture System: An advanced in vitro system enabling quantitative assessment of myelin damage and restoration in a stable, long-term culture environment.
-
Rigorous In Vivo Validation: Candidates undergo comprehensive testing in CMT1A transgenic models, utilizing myelin morphometry, nerve conduction studies (NCS), and behavioral assays.
-
Multi-Parametric Profiling: We integrate efficacy data with safety biomarkers to define the Mechanism of Action (MoA) and PK/PD profiles, ensuring high clinical translatability.
Through this platform, CELLTIUM identifies First-in-Class small molecules and ADCs with robust myelin-restorative activity.
